Question 1

What is pharmacogenomics in oncology?

Accepted Answer

Pharmacogenomics examines how inherited genetic variation may affect medication response. In oncology, PGx can add information about how inherited genetics may affect a patient's response to certain medications.

Question 2

Where should an oncology program start with PGx?

Accepted Answer

A practical starting point is to prioritize gene–drug pairs where the evidence is strong, the clinical consequences matter and there is a clear action to consider. Programs can then build the processes needed around clearer initial use cases before considering expansion.

Question 3

Does an oncology program need to implement every PGx application at once?

Accepted Answer

No. Programs can start with clearer use cases, establish the processes needed to support them and consider additional applications over time.

Question 4

Want to explore what PGx could look like in oncology?

Accepted Answer

Explore oncology-specific PGx education, including why prioritization matters, an educational overview of DPYD and additional resources to help you take the next step.

Where to Start with Pharmacogenomics in Oncology

Practical Strategies for Improving Reimbursement for Genetic and Molecular Testing

Managing Reimbursement for Molecular Testing in Infectious Disease

Companion Diagnostics and HLA Typing: Enabling the Future of Precision Medicine

Wastewater as a Window to Public Health: Unlocking Microbial Insights with Digital PCR

Advancing Women’s Health Research Through Microbiome Innovation

From One-Size-Fits-All to Precision Care: Personalizing Therapy in Transplantation

Refining HLA-DQ Eplet Definition: Alpha-Chain, Beta-Chain and Cross-Chain Antibody Targets Revealed by Advanced DQ Single Antige...

Beyond the Surgery: Comprehensive Monitoring in Organ Transplant Recipients